Activation of corticotropin releasing factor receptor type 2 in the heart by corticotropin releasing factor offers cytoprotection against ischemic injury via PKA and PKC dependent signaling

Regulatory Peptides

Volumn 174, Issue 1-3, 2012, Pages 90-97

  Jonassen, Anne K ^a   Wergeland, Anita ^a   Helgeland, Erik ^a   Mjøs, Ole D ^b   Brar, Bhawanjit K ^c,d  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Apoptosis; Cardioprotection; CRF; CRFR2; Ischemia; PKA; PKC

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ASTRESSIN; ASTRESSIN 2B; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROTECTION; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; ENZYME INHIBITION; EX VIVO STUDY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; IN VITRO STUDY; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REOXYGENATION; REPERFUSION INJURY; SIGNAL TRANSDUCTION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; BRAIN ISCHEMIA; CELL DEATH; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HEART; ISOQUINOLINES; MICE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; PROTEIN KINASE C; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

MURINAE; RATTUS;

EID: 84856464368     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2011.12.005     Document Type: Article

References (51)

1. Lovenberg T.W., Chalmers D.T., Liu C., De Souza E.B. CRF2 alpha and CRF2 beta receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology 1995, 136:4139-4142.
2. Perrin M., Donaldson C., Chen R., Blount A., Berggren T., Bilezikjian L., et al. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc Natl Acad Sci U S A 1995, 92:2969-2973.
3. Spiess J., Rivier J., Rivier C., Vale W. Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci 1981, 78:6517-6521.
4. Hashimoto K., Nishiyama M., Tanaka Y., Noguchi T., Asaba K., Hossein P.N., et al. Urocortins and corticotropin releasing factor type 2 receptors in the hypothalamus and the cardiovascular system. Peptides 2004, 25:1711-1721.
5. Theoharides T.C., Donelan J.M., Papadopoulou N., Cao J., Kempuraj D., Conti P. Mast cells as targets of corticotropin-releasing factor and related peptides. Trends Pharmacol Sci 2004, 25:563-568.
6. Harbuz M. Neuroendocrinology of autoimmunity. Int Rev Neurobiol 2002, 52:133-161.
7. Wood S.K., Woods J.H. Corticotropin-releasing factor receptor-1: a therapeutic target for cardiac autonomic disturbances. Expert Opin Ther Targets 2007, 11:1401-1413.
8. Baigent S.M., Lowry P.J. mRNA expression profiles for corticotrophin-releasing factor (CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues. J Mol Endocrinol 2000, 25:43-52.
9. Brar B.K., Jonassen A.K., Egorina E.M., Chen A., Negro A., Perrin M.H., et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 2004, 145:24-35.
10. Stiedl O., Meyer M., Jahn O., Ogren S.O., Spiess J. Corticotropin-releasing factor receptor 1 and central heart rate regulation in mice during expression of conditioned fear. J Pharmacol Exp Ther 2005, 312:905-916.
11. Grunt M., Haug C., Duntas L., Pauschinger P., Maier V., Pfeiffer E.F. Dilatory and inotropic effects of corticotropin-releasing factor (CRF) on the isolated heart. Effects on atrial natriuretic peptide (ANP) release. Horm Metab Res 1992, 24:56-59.
12. Richter R.M., Mulvany M.J. Comparison of hCRF and oCRF effects on cardiovascular responses after central, peripheral, and in vitro application. Peptides 1995, 16:843-849.
13. Saitoh M., Hasegawa J., Mashiba H. Effect of corticotropin-releasing factor on the electrical and mechanical activities of the guinea-pig ventricular myocardium. Gen Pharmacol 1990, 21:337-342.
14. Brar B.K., Stephanou A., Okosi A., Lawrence K.M., Knight R.A., Marber M.S., et al. CRH-like peptides protect cardiac myocytes from lethal ischaemic injury. Mol Cell Endocrinol 1999, 158:55-63.
15. Brar B.K., Jonassen A.K., Stephanou A., Santilli G., Railson J., Knight R.A., et al. Urocortin protects against ischemic and reperfusion injury via a MAPK-dependent pathway. J Biol Chem 2000, 275:8508-8514.
16. Lawrence K.M., Kabir A.M., Bellahcene M., Davidson S., Cao X.B., McCormick J., et al. Cardioprotection mediated by urocortin is dependent on PKCepsilon activation. FASEB J 2005, 19:831-833.
17. Rivier J., Gulyas J., Kirby D., Low W., Perrin M.H., Kunitake K., et al. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists. J Med Chem 2002, 45:4737-4747.
18. i. J Mol Cell Cardiol 1992, 24:937-948.
19. Szentandrássy N., Pérez-Bido M.R., Alonzo E., Negretti N., O'Neill S.C. Protein kinase A is activated by the n-3 polyunsaturated fatty acid eicosapentaenoic acid in rat ventricular muscle. J Physiol 2007, 582:349-358.
20. Alessi D.R., Cuenda A., Cohen P., Dudley D.T., Saltiel A.R. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem 1995, 270:27489-27494.
21. Simpson P., Savion S. Differentiation of rat myocytes in single cell cultures with and without proliferating nonmyocardial cells. Cross-striations, ultrastructure, and chronotropic response to isoproterenol. Circ Res 1982, 50:101-116.
22. Frankfurt O.S., Krishan A. Enzyme-linked immunosorbent assay (ELISA) for the specific detection of apoptotic cells and its application to rapid drug screening. J Immunol Methods 2001, 253:133-144.
23. Jonassen A.K., Sack M.N., Mjøs O.D., Yellon D.M. Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 2001, 89:1191-1198.
24. Teoh Teoh L.K., Grant R., Hulf J.A., Pugsley W.B., Yellon D.M. The effect of preconditioning (ischemic and pharmacological) on myocardial necrosis following coronary artery bypass graft surgery. Cardiovasc Res 2002, 53:175-180.
25. Schulz R., Cohen M.V., Behrends M., Downey J.M., Heusch G. Signal transduction of ischemic preconditioning. Cardiovasc Res 2001, 52:181-198.
26. Chen R., Lewis K.A., Perrin M.H., Vale W.W. Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A 1993, 90:8967-8971.
27. Vita N., Laurent P., Lefort S., Chalon P., Lelias J.M., Kaghad M., et al. Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett 1993, 335:1-5.
28. Chang C.P., Pearse R.V., O'Connell S., Rosenfeld M.G. Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron 1993, 11:1187-1195.
29. Stenzel P., Kesterson R., Yeung W., Cone R.D., Rittenberg M.B., Stenzel-Poore M.P. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol Endocrinol 1995, 9:637-645.
30. Kishimoto T., Pearse R.V., Lin C.R., Rosenfeld M.G. A sauvagine/corticotropin-releasing factor receptor expressed in heart and skeletal muscle. Proc Natl Acad Sci U S A 1995, 92:1108-1112.
31. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A 1995, 92:836-840.
32. Chen A., Perrin M., Brar B., Li C., Jamieson P., Digruccio M., et al. Mouse corticotropin-releasing factor receptor type 2alpha gene: isolation, distribution, pharmacological characterization and regulation by stress and glucocorticoids. Mol Endocrinol 2005, 19:441-458.
33. Brar B.K., Stephanou A., Okosi A., Lawrence K.M., Knight R.A., Marber M.S., et al. CRH-peptides protect cardiomyocytes from lethal ischaemic injury. Mol Cell Endocrinol 1999, 158:55-56.
34. Okosi A., Brar B.K., Chan M., D'Souza L., Smith E., Stephanou A., et al. Expression and protective effects of urocortin in cardiomyocytes. Neuropeptides 1998, 32:167-171.
35. Baigent S.M., Lowry P.J. mRNA expression profiles for corticotrophinreleasing factor (CRF), urocortin, CRF receptors and CRF-binding protein in peripheral rat tissues. J Mol Endocrinol 2000, 25:43-52.
36. Makino S., Asaba K., Takao T., Hashimoto K. Type 2 corticotropin-releasing hormone receptor mRNA expression in the heart in hypertensive rats. Life Sci 1998, 62:515-523.
37. Brar B.K., Chen A., Perrin M.H., Vale W. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2beta by the CRF/urocortin family of peptides. Endocrinology 2004, 145:1718-1729.
38. Perrin M.H., Grace C.R., Digruccio M.R., Fischer W.H., Maji S.K., Cantle J.P., et al. Distinct structural and functional roles of conserved residues in the first extracellular domain of receptors for corticotropin-releasing factor and related G-protein-coupled receptors. J Biol Chem 2007, 282:37529-37536.
39. Grace C.R., Perrin M.H., Cantle J.P., Vale W.W., Rivier J.E., Riek R. Common and divergent structural features of a series of corticotropin releasing factor-related peptides. J Am Chem Soc 2007, 129:16102-16114.
40. Morel E., Marcantoni A., Gastineau M., Birkedal R., Rochais F., Garnier A., et al. cAMP-binding protein Epac induces cardiomyocyte hypertrophy. Circ Res 2005, 97:1296-1304. [23].
41. Pereira L., Métrich M., Fernández-Velasco M., Lucas A., Leroy J., Perrier R., et al. The cAMP binding protein Epac modulates Ca2{Thorn} sparks by a Ca2{Thorn}/calmodulin kinase signalling pathway in rat cardiac myocytes. J Physiol 2007, 583:685-694.
42. Calderón-Sanchez E., Delgado C., Ruiz-Hurtado G., Domínguez-Rodríguez A., Cachofeiro V., Rodríguez-Moyano M., et al. Urocortin induces positive inotropic effect in rat heart. Cardiovasc Res 2009, 83:717-725.
43. Smani T., Calderón-Sanchez E., Gómez-Hurtado N., Fernández-Velasco M., Cachofeiro V., Lahera V., et al. Mechanisms underlying the activation of L-type calcium channels by urocortin in rat ventricular myocytes. Cardiovasc Res 2010, 87:459-466.
44. Markovic D., Punn A., Lehnert H., Grammatopoulos D.K. Molecular determinants and feedback circuits regulating type 2 CRH receptor signal integration. Biochim Biophys Acta 2011, 1813:896-907.
45. Traver S., Marien M., Martin E., Hirsch E.C., Michel P.P. The phenotypic differentiation of locus ceruleus noradrenergic neurons mediated by brain-derived neurotrophic factor is enhanced by corticotropin releasing factor through the activation of a cAMP-dependent signaling pathway. Mol Pharmacol 2006, 70:30-40.
46. Van Kolen K., Dautzenberg F.M., Verstraeten K., Royaux I., De Hoogt R., Gutknecht E., et al. Corticotropin releasing factor-induced ERK phosphorylation in AtT20 cells occurs via a cAMP-dependent mechanism requiring EPAC2. Neuropharmacology 2010, 58:135-144.
47. Pedersen W.A., Wan R., Zhang P., Mattson M.P. Urocortin, but not urocortin II, protects cultured hippocampal neurons from oxidative and excitotoxic cell death via corticotropin-releasing hormone receptor type I. J Neurosci 2002, 22:404-412.
48. Bayatti N., Zschocke J., Behl C. Brain region-specific neuroprotective action and signaling of corticotropin-releasing hormone in primary neurons. Endocrinology 2003, 144:4051-4060.
49. Rissman R.A., Lee K.F., Vale W., Sawchenko P.E. Corticotropin-releasing factor receptors differentially regulate stress-induced tau phosphorylation. J Neurosci 2007, 27:6552-6562.
50. Lochner A., Moolman J.A. The many faces of H89: a review. Cardiovasc Drug Rev 2006, 24(3-4):261-274. [Review].
51. Stensløkken K.O., Rutkovskiy A., Kaljusto M.L., Hafstad A.D., Larsen T.S., Vaage J. Inadvertent phosphorylation of survival kinases in isolated perfused hearts: a word of caution. Basic Res Cardiol 2009, 104(4):412-423.